Side Effects of Male Cancers - Better Survival and Growing Social Acceptance of Impotence and Urinary Incontinence Equates to New Opportunities for Drug Therapies - Market Research Reports

Contents:

Overview

Introduction

Male Cancers

DRIVERS AND TRENDS

Key drivers of the market for new approaches to the treatment of the side effects of male cancers include increasing prevalence, increased visibility and acknowledgement for side effects such as impotence and incontinence, increased long-term survival leading to higher unmet need, and the commercial success of products now entering the niche.

There will be higher consumer and physician demand for effective pharmaceuticals.
Successful pharmaceuticals are likely to achieve commercial success because of significant patient populations and high unmet need.

ETIOLOGY AND PREVALENCE

Identifies the side effects of male cancers that are the greatest barriers to compliance and post-therapy quality of life. Projects the number of men who are candidates for pharmaceutical therapy for side effects. Explains the etiology and male cancer-specific frequency of impotence, incontinence, bone pain and emotional changes—the hallmarks of therapy for many male cancers, and severe enough to prevent or delay therapy in a significant population of men.

PHARMACOLOGICAL APPROACHES

Updates R&D managers on the clinical and commercial status of current and pipeline agents for male cancers side effects. Products profiled include PEG5 erectile function drugs, incontinence, agents to control bone pain and antidepressants commonly used in cancer patients.

ACTION POINTS

Prostate cancer is associated with the greatest unmet needs in terms of side effects for male cancers and their treatment.
Pharmacological approaches to erectile dysfunction after prostate cancer offer the greatest commercial potential in addressing unmet needs associated with male cancer side effects
There is a clinical and commercial gap between pharmaceutical approaches to managing the side effects of female cancers compared to those used for male cancers. Closing this gap would translate into considerable commercial gain.

COMPARISONS WITH APPROACHES FOR WOMEN’S CANCERS

Gives insight into the historical factors behind the unmet needs in male cancers side effects by comparing this indication with that for the more-prevalent, more visible women’s cancers.

The side effects of male cancers have received less pharmaceutical attention than have those associated with female cancers; the imbalance may be attributable to differences in disease prevalence, to cultural and psychological differences between men and women’s approaches to disease or to the history of greater commercial success associated with women’s cancer therapies.

Male cancers education and R&D are associated with fewer political, educational or philanthropic efforts. Pharmaceutical companies interested in expanding the commercial potential of their male cancers drugs could most likely achieve greater visibility, with relatively little financial investment, by establishing or working with a male cancer foundation on behalf of patient and physician education and private research funding.